Continued Losses and Negative Retained Earnings Carried Forward
First written in FY2016. 23 of 42 entries say "Mitigated", first in FY2017-Q1. Latest entry: 2026-10-30.
The whole theme swung hardest in 2021: 8 of 11 companies on the "Worse" side.
2 other companies' latest entry also says "Mitigated".
- FY2026WorsenedAnnual report
「Net sales for the fiscal year were ¥2,182.745 million, down 11.1% year on year. Operating loss was ¥549.445 million, compared with an operating loss of ¥238.315 million in the previous fiscal year. Ordinary loss was ¥537.443 million, compared with an ordinary loss of ¥234.487 million, and net loss for the year was ¥734.751 million, compared with a net loss of ¥255.304 million.」
From a full-year deficit in the previous fiscal year, operating, ordinary and net losses all widened in the current fiscal year due to lower sales, as well as the impact of sales promotion expenses and other factors. The company also recorded an impairment loss on investment securities of ¥149.999 million and other losses. - FY2026-H1WorsenedAnnual report
「Operating loss was ¥376.092 million, compared with an operating loss of ¥207.326 million in the same period of the previous year. Ordinary loss was ¥369.121 million, compared with an ordinary loss of ¥206.402 million, and interim net loss was ¥371.350 million, compared with an interim net loss of ¥225.312 million.」
After returning to full-year profitability in the previous fiscal year, operating loss, ordinary loss and interim net loss widened significantly year on year during the interim accounting period, further worsening the company’s position regarding continuing losses. - FY2025WorsenedAnnual report
「In the 27th fiscal year, the company reported an ordinary loss and a net loss for the year due to lower net sales and higher research and development expenses related to advancing the development of new pipeline products.」
After returning to full-year profitability in the previous fiscal year, the company reported an ordinary loss of ¥234.487 million and a net loss of ¥255.304 million for the current fiscal year, due to lower sales and higher research and development expenses for new pipeline products. - FY2025-H1WorsenedAnnual report
「The operating loss was ¥207,326 thousand, compared with an operating loss of ¥10,852 thousand in the same period of the previous year. Ordinary loss was ¥206,402 thousand, compared with an ordinary loss of ¥9,731 thousand, and interim net loss was ¥225,312 thousand, compared with an interim net loss of ¥11,633 thousand.」
After returning to full-year profitability in the fiscal year ended March 2024, operating loss, ordinary loss and interim net loss widened significantly year on year during the interim accounting period, and the company’s position regarding continuing losses deteriorated again. - FY2024MitigatedAnnual report
「In the 26th fiscal year, the company recorded ordinary profit and net profit for the fiscal year due to a substantial increase in revenue from its regenerative medicine contract business, as well as reductions in selling, general and administrative expenses.」
After a period of continuing operating loss, ordinary loss and net loss for the fiscal year, the company recorded operating profit of ¥144,506 thousand, ordinary profit of ¥147,009 thousand and net profit for the fiscal year of ¥143,169 thousand in the fiscal year ended March 2024, substantially reducing the risk of recurring losses. - FY2024-Q3MitigatedAnnual report
「The operating loss was ¥51,669 thousand, compared with an operating loss of ¥624,460 thousand in the same period of the previous year. Ordinary loss was ¥50,729 thousand, compared with an ordinary loss of ¥622,797 thousand, and net loss for the quarter was ¥53,581 thousand, compared with a net loss of ¥625,649 thousand.」
Operating loss, ordinary loss and net loss for the quarter all narrowed significantly from the same period of the previous year. Losses themselves continued during the nine-month cumulative period. - FY2024-Q2MitigatedAnnual report
「The operating loss was ¥10,852 thousand, compared with an operating loss of ¥420,008 thousand in the same period of the previous year. Ordinary loss was ¥9,731 thousand, compared with an ordinary loss of ¥419,490 thousand, and net loss for the quarter was ¥11,633 thousand, compared with a net loss of ¥421,392 thousand.」
Operating loss, ordinary loss and net loss for the quarter all narrowed significantly from the same period of the previous year. However, losses continued during the six-month cumulative period. - FY2024-Q1MitigatedAnnual report
「Operating profit was ¥14,212 thousand, compared with an operating loss of ¥267,091 thousand in the same period of the previous year. Ordinary profit was ¥14,788 thousand, compared with an operating loss of ¥267,257 thousand, and net profit for the quarter was ¥13,837 thousand, compared with a net loss of ¥268,208 thousand.」
The company changed from the operating loss, ordinary loss and net loss that had continued through the previous year to operating profit, ordinary profit and net profit for the quarter in the first quarter. As sustained profitability for the full fiscal year has not been confirmed, the risk is treated as having declined. - FY2023-Q3WorsenedAnnual report
「The operating loss was ¥624,460 thousand, compared with an operating loss of ¥339,645 thousand in the same period of the previous year. Ordinary loss was ¥622,797 thousand, compared with an ordinary loss of ¥337,552 thousand, and net loss for the quarter was ¥625,649 thousand, compared with a net loss of ¥340,601 thousand.」
Operating loss, ordinary loss and net loss for the nine-month cumulative period all increased from the same period of the previous year, worsening the recurring loss position. - FY2023-Q2WorsenedAnnual report
「The operating loss was ¥420,008 thousand, compared with an operating loss of ¥267,960 thousand in the same period of the previous year. Ordinary loss was ¥419,490 thousand, compared with an ordinary loss of ¥265,474 thousand, and net loss for the quarter was ¥421,392 thousand, compared with a net loss of ¥267,571 thousand.」
Operating loss, ordinary loss and net loss for the six-month cumulative period all increased from the same period of the previous year, worsening the recurring loss position. - FY2023-Q1WorsenedAnnual report
「The operating loss was ¥267,091 thousand, compared with an operating loss of ¥129,762 thousand in the same period of the previous year. Ordinary loss was ¥267,257 thousand, compared with an ordinary loss of ¥128,332 thousand, and net loss for the quarter was ¥268,208 thousand, compared with a net loss of ¥129,478 thousand.」
Operating loss, ordinary loss and net loss for the quarter all increased from the same period of the previous year, worsening the recurring loss position. - FY2022WorsenedAnnual report
「The company recorded ordinary loss and net loss for the fiscal year due to a decrease in revenue and increased research and development expenses associated with advancing product development.」
Revenue for the fiscal year was ¥2,103,443 thousand, operating loss was ¥498,182 thousand, ordinary loss was ¥494,049 thousand, and net loss for the fiscal year was ¥497,889 thousand. Operating loss, ordinary loss and net loss for the fiscal year all increased from the previous fiscal year. - FY2022-Q3MitigatedAnnual report
「The operating loss was ¥339,645 thousand, compared with an operating loss of ¥410,050 thousand in the same period of the previous year. Ordinary loss was ¥337,552 thousand, compared with an ordinary loss of ¥407,055 thousand, and net loss for the quarter was ¥340,601 thousand, compared with a net loss of ¥410,135 thousand.」
Operating loss, ordinary loss and net loss for the quarter all narrowed from the same period of the previous year, improving the scale of recurring losses. However, the losses themselves continued. - FY2022-Q2MitigatedAnnual report
「The operating loss was ¥267,960 thousand, compared with an operating loss of ¥272,279 thousand in the same period of the previous year. Ordinary loss was ¥265,474 thousand, compared with an ordinary loss of ¥270,150 thousand, and net loss for the quarter was ¥267,571 thousand, compared with a net loss of ¥272,279 thousand.」
Operating loss, ordinary loss and net loss for the quarter all narrowed from the same period of the previous year, slightly improving the scale of the losses. However, the losses themselves continued. - FY2022-Q1MitigatedAnnual report
「The operating loss was ¥129,762 thousand, compared with an operating loss of ¥174,692 thousand in the same period of the previous year, representing an improvement year on year. Ordinary loss was ¥128,332 thousand, compared with an ordinary loss of ¥173,724 thousand, and net loss for the quarter was ¥129,478 thousand, compared with a net loss of ¥174,873 thousand.」
Operating loss, ordinary loss and net loss for the quarter all narrowed from the same period of the previous year. However, losses continued in the first quarter. - FY2021-Q3WorsenedAnnual report
「The operating loss was ¥410,050 thousand, compared with an operating loss of ¥363,865 thousand in the same period of the previous year. Ordinary loss was ¥407,055 thousand, compared with an ordinary loss of ¥359,850 thousand, and net loss for the quarter was ¥410,135 thousand, compared with a net loss of ¥362,845 thousand.」
Operating loss, ordinary loss and net loss for the nine-month cumulative period all increased from the same period of the previous year, worsening the recurring loss position. - FY2021-Q2RestatedAnnual report
「The operating loss was ¥272,279 thousand, compared with an operating loss of ¥271,801 thousand in the same period of the previous year. Ordinary loss was ¥270,150 thousand, compared with an ordinary loss of ¥269,058 thousand, and net loss for the quarter was ¥272,279 thousand, compared with a net loss of ¥271,106 thousand.」
Operating loss, ordinary loss and net loss for the quarter continued at roughly the same levels as in the same period of the previous year, leaving the risk of losses still present. - FY2021-Q1MitigatedAnnual report
「The operating loss was ¥174,692 thousand, compared with an operating loss of ¥184,798 thousand in the same period of the previous year, representing an improvement year on year. Ordinary loss was ¥173,724 thousand, compared with an ordinary loss of ¥183,333 thousand, and net loss for the quarter was ¥174,873 thousand, compared with a net loss of ¥184,457 thousand.」
Operating loss, ordinary loss and net loss for the quarter all narrowed from the same period of the previous year. However, losses continued in the first quarter. - FY2020MitigatedAnnual report
「The operating loss was ¥235,178 thousand, compared with an operating loss of ¥349,745 thousand in the same period of the previous year, representing an improvement from the previous year, when the company paid an upfront fee for the introduction of in-house CAR-T cell therapy. Ordinary loss was ¥229,777 thousand and net loss for the fiscal year was ¥287,099 thousand.」
The operating loss narrowed from the same period of the previous year, but ordinary loss and net loss for the fiscal year continued, leaving the risk of recurring losses reduced but still present. - FY2020-Q3MitigatedAnnual report
「The operating loss was ¥363,865 thousand, compared with an operating loss of ¥480,915 thousand in the same period of the previous year, representing an improvement from the previous year, when the company made upfront and other payments for the introduction of in-house CAR-T cell therapy. Ordinary loss was ¥359,850 thousand, compared with an ordinary loss of ¥472,678 thousand, and net loss for the quarter was ¥362,845 thousand, compared with a net loss of ¥485,478 thousand.」
Operating loss, ordinary loss and net loss for the quarter all narrowed from the same period of the previous year, but the losses themselves continued. - FY2020-Q2MitigatedAnnual report
「The operating loss was ¥271,801 thousand, compared with an operating loss of ¥423,101 thousand in the same period of the previous year, representing an improvement from the previous year, when the company made upfront and other payments for the introduction of in-house CAR-T cell therapy. Ordinary loss was ¥269,058 thousand, compared with an ordinary loss of ¥418,086 thousand, and net loss for the quarter was ¥271,106 thousand, compared with a net loss of ¥415,276 thousand.」
Operating loss, ordinary loss and net loss for the quarter all narrowed from the same period of the previous year. However, losses continued during the six-month cumulative period. - FY2020-Q1MitigatedAnnual report
「The operating loss was ¥184,798 thousand, compared with an operating loss of ¥441,616 thousand in the same period of the previous year, representing an improvement from the previous year, when the company made upfront and other payments for the introduction of in-house CAR-T cell therapy. Ordinary loss was ¥183,333 thousand, compared with an ordinary loss of ¥438,973 thousand, and net loss for the quarter was ¥184,457 thousand, compared with a net loss of ¥440,169 thousand.」
Operating loss, ordinary loss and net loss for the quarter all narrowed from the same period of the previous year. The company states that the absence of upfront and other payments for the introduction of in-house CAR-T cell therapy incurred in the previous year was a factor behind the improvement, but losses continued in the current quarter. - FY2019RestatedAnnual report
「Due in part to increased research and development expenses, including development costs and clinical trial expenses, as well as upfront payments for the introduction of in-house CAR-T cell therapy, the company recorded an operating loss of ¥349,745 thousand, compared with operating profit of ¥211,508 thousand in the same period of the previous year. Ordinary loss was ¥339,631 thousand, compared with ordinary profit of ¥213,334 thousand, and net loss for the fiscal year was ¥333,248 thousand, compared with net profit of ¥227,890 thousand.」
Against a backdrop of increased development and clinical trial expenses for new pipelines, the company recorded an operating loss, ordinary loss and net loss for the full fiscal year. - FY2019-Q3RestatedAnnual report
「In addition, due to increased research and development expenses for new pipelines, the company recorded an operating loss of ¥480,915 thousand, compared with operating profit of ¥121,548 thousand in the same period of the previous year. Ordinary loss was ¥472,678 thousand, compared with ordinary profit of ¥121,332 thousand, and net loss for the quarter was ¥485,478 thousand, compared with net profit of ¥106,324 thousand.」
Against a backdrop of increased research and development expenses for new pipelines, the company shifted from profit in the same period of the previous year to operating loss, ordinary loss and net loss for the quarter in the nine-month cumulative period. - FY2019-Q2RestatedAnnual report
「In addition, due to increased research and development expenses for new pipelines, the company recorded an operating loss of ¥423,101 thousand, compared with operating profit of ¥84,900 thousand in the same period of the previous year. Ordinary loss was ¥418,086 thousand, compared with ordinary profit of ¥84,102 thousand, and net loss for the quarter was ¥415,276 thousand, compared with net profit of ¥67,028 thousand.」
Against a backdrop of increased research and development expenses for new pipelines, operating loss, ordinary loss and net loss for the quarter continued during the six-month cumulative period. - FY2019-Q1MaterialisedAnnual report
「In addition, due to increased research and development expenses for new pipelines, the company recorded an operating loss of ¥441,616 thousand, compared with operating profit of ¥6,032 thousand in the same period of the previous year. Ordinary loss was ¥438,973 thousand, compared with ordinary profit of ¥5,561 thousand, and net loss for the quarter was ¥440,169 thousand, compared with net profit of ¥3,492 thousand.」
Although the company had achieved operating profit through the previous fiscal year, it recorded operating loss, ordinary loss and net loss for the quarter in the first quarter due to increased research and development expenses for new pipelines, and the risk of losses materialized. - FY2018MitigatedAnnual report
「The company achieved an operating profit for the fiscal year, as it did in the previous fiscal year.」
The company achieved operating profit for 2 consecutive fiscal years and recorded net profit of ¥227,890 thousand and retained earnings of ¥504,132 thousand, further reducing the risks related to recurring losses and negative retained earnings. However, achieving a stable profitable business remains the company’s top priority. - FY2018-Q3MitigatedAnnual report
「Due to increased gross profit accompanying strong sales, operating profit was ¥121,548 thousand, compared with an operating loss of ¥198,933 thousand in the same period of the previous year, resulting in an operating profit for the nine-month cumulative period following the operating profit for the six-month cumulative period. Ordinary profit was ¥121,332 thousand, compared with an ordinary loss of ¥200,755 thousand in the same period of the previous year, and net profit for the quarter was ¥106,324 thousand, compared with a net loss of ¥203,605 thousand.」
The company also recorded operating profit, ordinary profit and net profit for the quarter for the nine-month cumulative period, improving its earnings position from the losses recorded in the same period of the previous year. - FY2018-Q2MitigatedAnnual report
「Operating profit was ¥84,900 thousand, compared with an operating loss of ¥161,847 thousand in the same period of the previous year, resulting in an operating profit for the six-month cumulative period following the operating profit in the first quarter. Ordinary profit was ¥84,102 thousand, compared with an ordinary loss of ¥162,984 thousand in the same period of the previous year, and net profit for the quarter was ¥67,028 thousand, compared with a net loss of ¥164,884 thousand.」
The company recorded an operating profit for the six-month cumulative period following the first quarter, and ordinary profit and net profit for the quarter also turned positive. The risk related to recurring losses declined further. - FY2018-Q1MitigatedAnnual report
「Operating profit was ¥6,032 thousand, compared with an operating loss of ¥121,412 thousand in the same period of the previous year, resulting in the first operating profit for a first-quarter cumulative period. Ordinary profit was ¥5,561 thousand, compared with an ordinary loss of ¥122,017 thousand in the same period of the previous year, and net profit for the quarter was ¥3,492 thousand, compared with a net loss of ¥122,967 thousand.」
Increased revenue and reductions in selling, general and administrative expenses resulted in the first operating profit for a first-quarter cumulative period, with ordinary profit and net profit for the quarter also turning positive. The risk of recurring losses declined, but this was based on the results of a single quarter. - FY2017-Q3MitigatedAnnual report
「As a result, revenue for the nine months ended 31 December was ¥1,154,311 thousand, up 20.7% year on year. Although the company recorded an operating loss of ¥198,933 thousand, compared with an operating loss of ¥605,425 thousand in the same period of the previous year, profitability improved due to reductions in selling, general and administrative expenses. Ordinary loss was ¥200,755 thousand, compared with an ordinary loss of ¥594,518 thousand in the same period of the previous year, and net loss for the quarter was ¥203,605 thousand, compared with a net loss of ¥597,368 thousand.」
Revenue increased 20.7% year on year, and operating loss, ordinary loss and net loss for the quarter all narrowed from the previous year. However, all three losses continued. - FY2017-Q2MitigatedAnnual report
「As a result, revenue for the six months ended 30 September was ¥766,865 thousand, up 10.1% year on year. Although the company recorded an operating loss of ¥161,847 thousand, compared with a loss of ¥371,943 thousand in the same period of the previous year, profitability improved due to reductions in selling, general and administrative expenses.」
Revenue increased 10.1% year on year, and the operating loss narrowed from ¥371,943 thousand to ¥161,847 thousand. However, operating loss, ordinary loss and net loss for the quarter continued. - FY2017-Q1MitigatedAnnual report
「Profitability improved due to increased sales of Jack and reductions in selling, general and administrative expenses.」
Revenue increased 12.5% year on year, and the operating loss narrowed from ¥219,680 thousand in the same period of the previous year to ¥121,412 thousand. However, operating loss, ordinary loss and net loss for the quarter continued. - FY2016First statedAnnual report
「As described above, the company has continued to report operating losses and negative operating cash flow, but is working to increase sales centered on Jace and Jack and improve operating cash flow.」
For the fiscal year ended March 2016, the company reported an operating loss of ¥722,599 thousand, negative operating cash flow of ¥346,906 thousand, and negative retained earnings of ¥13,149,273 thousand.